Update on Lincoln Medical Final

RNS Number : 3604U
Allergy Therapeutics PLC
27 December 2012
 



27 December 2012   

 

Allergy Therapeutics plc
("Allergy Therapeutics" or "the Company")

 

Update on Anapen®

 

Allergy Therapeutics plc (AIM: AGY), the fully integrated specialty pharmaceutical company, announces that it has terminated the agreement with Lincoln Medical Limited, the producer of Anapen® (adrenaline for injection), for the Anapen® distribution rights in a number of countries.

 

On 23 May 2012 Allergy Therapeutics reported that Lincoln Medical was undertaking a voluntary drug recall of Anapen® for all unexpired units of the product in the UK, as a precautionary measure. The voluntary recall was related to a potential problem with delivery time and delivery volume of the dosage following activation of the auto-injector. Allergy Therapeutics has, after due consideration, decided to terminate its agreement with Lincoln Medical.

 

Manuel Llobet, Chief Executive Officer, commented:

 

"The board has decided that terminating the arrangement with Lincoln Medical is in the best interests of the Company. Although disappointing to lose a product line, the Anapen® contract did deliver a net positive return to the Company. Diversification into other geographies and product in-licensing opportunities continue to be explored in line with the Group's strategy for growth."

 

-Ends-

 

For further information

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

 

Ian Postlethwaite, Finance Director

 

www.allergytherapeutics.com

 

 

 

Nomura Code Securities

+44 (0) 207 776 1200

Juliet Thompson/ Clare Terlouw

 

 

 

FTI Consulting

+44 (0) 207 831 3113

Simon Conway/Susan Stuart


 

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving gross sales for the previous financial year of £43.8 million, mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUBUKRUAAUURA
UK 100

Latest directors dealings